HN2302
/ Shenzhen MagicRNA Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 13, 2026
AID: Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Initiation date: Apr 2026 ➔ Dec 2026
Trial initiation date • Immunology • Inflammatory Arthritis • Lupus • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis
1 to 1
Of
1
Go to page
1